Invention Grant
US08497300B2 Arsenic therapy for APLS-type autoimmune lymph-oproliferative syndrome in mice and humans
有权
砷治疗APLS型自身免疫性淋巴细胞增生综合征的小鼠和人类
- Patent Title: Arsenic therapy for APLS-type autoimmune lymph-oproliferative syndrome in mice and humans
- Patent Title (中): 砷治疗APLS型自身免疫性淋巴细胞增生综合征的小鼠和人类
-
Application No.: US12244732Application Date: 2008-10-02
-
Publication No.: US08497300B2Publication Date: 2013-07-30
- Inventor: Kmar Chelbi Alix , Pedro Bobe
- Applicant: Kmar Chelbi Alix , Pedro Bobe
- Applicant Address: FR Paris
- Assignee: Centre National de la Recherche Scientifique (CNRS)
- Current Assignee: Centre National de la Recherche Scientifique (CNRS)
- Current Assignee Address: FR Paris
- Agency: Foley & Lardner LLP
- Priority: FR0205276 20020426
- Main IPC: A01N59/22
- IPC: A01N59/22 ; A01N55/02 ; A61K33/36
Abstract:
The invention relates to the use of an arsenic compound for the preparation of a medicament that is used to treat autoimmune diseases.
Public/Granted literature
- US20090098216A1 ARSENIC THERAPY FOR APLS-TYPE AUTOIMMUNE LYMPH-OPROLIFERATIVE SYNDROME IN MICE AND HUMANS Public/Granted day:2009-04-16
Information query
